New drug combo shows promise for Hard-to-Treat cancers
Disease control
Completed
This study tested a new oral drug called RP-3500 (camonsertib) alone or combined with talazoparib or gemcitabine in 276 adults with advanced solid tumors that have certain gene mutations. The main goals were to find the safest dose and check for side effects. The study also looke…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:03 UTC